- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05397613
STAIR for Trauma and Emotion Dysregulation
25 maj 2022 uppdaterad av: Sanno Zack, Stanford University
Examining the Effectiveness of STAIR as an Alternative to DBT for Patients With Emotion Dysregulation and PTSD
This study will examine the impact of Skills Training in Affective and Interpersonal Regulation (STAIR) group, using self-report measures, on Posttraumatic Stress Disorder (PTSD), emotional dysregulation, borderline personality disorder symptoms, global psychopathology, and access to quality mental health care.
Aims include assessing the feasibility of STAIR, reducing patients' trauma and emotion dysregulation symptoms, examining whether STAIR may be used as an alternative to DBT for patients on the DBT, and improving patient satisfaction and clinic efficiency
Studieöversikt
Status
Anmälan via inbjudan
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Förväntat)
30
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
California
-
Stanford, California, Förenta staterna, 94305
- Stanford University
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Be 18 years or older.
- Have a DSM-5 diagnosis and/or symptoms for which DBT is an indicated treatment
- Meet DSM-5 criteria for a diagnosis of posttraumatic stress disorder (PTSD)
- Meet criteria at a subclinical level for BPD (a minimum of three symptoms)
- Must be able to make group commitments for attendance, safety, and sobriety during group
Exclusion Criteria:
- If currently receiving individual therapy that follows the DBT protocol or is an evidence-based trauma-focused therapy
- If the STAIR therapy group is determined to be clinically contraindicated
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: STAIR
Participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR).
Participants will complete self-report measures pre, post, and at one month intervals.
|
Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials.
STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
|
|
Experimentell: Waitlist control
First, participants will remain on the DBT waitlist for 12 weeks receiving no active intervention and will complete pre and post-measures.
Then participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR).
Participants will complete self-report measures pre, post, and at one month intervals.
|
Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials.
STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of participants who complete the STAIR intervention
Tidsram: Week 12
|
This number will include those who attend the 12 weeks of STAIR with no more than three missed sessions
|
Week 12
|
|
Total score of patient treatment satisfaction ratings
Tidsram: Week 12
|
Calculate the total score for each participant on the Client Satisfaction Questionnaire-8, and find the average of those scores.
Scores are summed across items.
Items 2, 4, 5, and 8 are reverse scored.
Total scores range from 8 to 32, with the higher number indicating greater satisfaction.
|
Week 12
|
|
Frequency of participant attendance
Tidsram: Week 1 through Week 12
|
Calculate the number of patients who attended each week of the STAIR treatment.
|
Week 1 through Week 12
|
|
Change in emotion regulation total score from baseline to Week 12
Tidsram: Baseline to Week 12
|
Problems with emotion regulation will be assessed using the Difficulty in Emotion Regulation Scale.
Total score ranges from 36 to 180.
Higher scores indicate greater problems with emotion regulation.
|
Baseline to Week 12
|
|
Change in the severity of posttraumatic stress disorder symptom total score from baseline to Week 12
Tidsram: Baseline to Week 12
|
The severity of posttraumatic stress disorder symptoms is measured using the PCL-5.
Items are rated using a 5-point likert scale ranging from 0 "not at all" to 4 "extremely."
All 20 items are summed to obtain a total score (0 to 80), higher scores indicate higher severity of PTSD symptoms.
|
Baseline to Week 12
|
|
Change in Borderline symptom severity total score from baseline to Week 12
Tidsram: Baseline and Week 12
|
Using the Borderline Evaluation of Severity Scale comprising of 15 items using a likert scale rated from 5 "Almost Always" to 1 "Almost Never."
There are three subscales that comprise this measure: (1) Thoughts and Emotions (2) Behaviors-Negative and (3) Behaviors-Positive.
The total for each subscale is determined to score the BEST.
The scores of subscales A and B are then added together and the total from subscale C is subtracted.
A correction factor of 15 is added to yield the final score which can range from 12 (best) to 72 (worst).
|
Baseline and Week 12
|
|
Change in Borderline Symptom List-23 total score from baseline to Week 12
Tidsram: Baseline and Week 12
|
This measure assesses feelings and experiences commonly endorsed by patients with BPD.
The 23-item scale utilizes a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very strong."
The BSL-23 is scored by summing up the scores for all of the items.
Total score ranges from 0 to 92, with higher scores reflecting more severe borderline personality symptoms.
|
Baseline and Week 12
|
|
Change in current symptoms of psychopathology and psychological distress total score from baseline to Week 12
Tidsram: Baseline and Week 12
|
The Symptom Checklist-90-Revised is a 90-item multidimensional self-report symptom measure that assesses current symptoms of psychopathology and psychological distress.
The items were scored on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely).
It assesses nine symptom dimensions (somatization, obsessive compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism).
Global measures are provided to summarize overall distress, and these include the Global Severity Index, Positive Symptom Distress Index, and Positive Symptom Total.
Raw scores are calculated by dividing the sum of scores for a specific dimension by the number of items in the dimension.
Global severity index is calculated by summing the scores of the nine dimensions and additional items, then dividing by the total number of responses.
Total score ranges from 0 to 360.
Higher scores indicate worsening of disease.
|
Baseline and Week 12
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Sanno Zack, PhD, Stanford Universtiy
- Huvudutredare: Emily Livermore, PsyD, Stanford University
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Förväntat)
15 juni 2022
Primärt slutförande (Förväntat)
15 juni 2025
Avslutad studie (Förväntat)
15 juni 2025
Studieregistreringsdatum
Först inskickad
24 maj 2022
Först inskickad som uppfyllde QC-kriterierna
25 maj 2022
Första postat (Faktisk)
31 maj 2022
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
31 maj 2022
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
25 maj 2022
Senast verifierad
1 maj 2022
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 64219
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .